| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 56 | 2021 | 170 | 11.330 |
Why?
|
| Graft Rejection | 25 | 2019 | 1052 | 3.500 |
Why?
|
| Immunosuppressive Agents | 18 | 2014 | 967 | 2.940 |
Why?
|
| Bronchiolitis Obliterans | 12 | 2019 | 31 | 2.670 |
Why?
|
| Primary Graft Dysfunction | 17 | 2018 | 27 | 2.040 |
Why?
|
| Sirolimus | 5 | 2014 | 166 | 1.850 |
Why?
|
| Lung | 12 | 2022 | 1122 | 1.350 |
Why?
|
| Lung Diseases, Interstitial | 6 | 2022 | 222 | 1.330 |
Why?
|
| Lung Diseases | 10 | 2018 | 258 | 1.140 |
Why?
|
| Postoperative Complications | 10 | 2016 | 2194 | 1.050 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 8 | 2022 | 149 | 1.040 |
Why?
|
| Frailty | 2 | 2020 | 34 | 0.940 |
Why?
|
| Cytomegalovirus Infections | 4 | 2013 | 144 | 0.910 |
Why?
|
| Tacrolimus | 4 | 2010 | 369 | 0.900 |
Why?
|
| Sarcopenia | 1 | 2020 | 13 | 0.800 |
Why?
|
| Patient Selection | 4 | 2021 | 680 | 0.760 |
Why?
|
| Hypertension, Pulmonary | 4 | 2018 | 332 | 0.760 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 40 | 0.680 |
Why?
|
| Bronchoscopy | 7 | 2022 | 144 | 0.610 |
Why?
|
| Prospective Studies | 20 | 2022 | 4076 | 0.600 |
Why?
|
| Biopsy | 6 | 2022 | 1139 | 0.600 |
Why?
|
| Reperfusion Injury | 3 | 2016 | 129 | 0.590 |
Why?
|
| Cytomegalovirus | 4 | 2006 | 76 | 0.570 |
Why?
|
| Middle Aged | 42 | 2022 | 24598 | 0.560 |
Why?
|
| Transplantation | 2 | 2006 | 39 | 0.560 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2016 | 120 | 0.550 |
Why?
|
| Humans | 76 | 2022 | 83576 | 0.550 |
Why?
|
| HLA-G Antigens | 1 | 2014 | 52 | 0.510 |
Why?
|
| Biomarkers | 13 | 2020 | 1647 | 0.510 |
Why?
|
| Male | 47 | 2022 | 40132 | 0.500 |
Why?
|
| Azathioprine | 2 | 2010 | 123 | 0.470 |
Why?
|
| Macrophages, Alveolar | 3 | 2018 | 55 | 0.460 |
Why?
|
| Genomics | 4 | 2022 | 664 | 0.460 |
Why?
|
| Female | 45 | 2022 | 43618 | 0.450 |
Why?
|
| Graft Survival | 8 | 2018 | 869 | 0.420 |
Why?
|
| Microbiota | 1 | 2014 | 362 | 0.350 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 252 | 0.350 |
Why?
|
| Time Factors | 12 | 2018 | 5174 | 0.350 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 143 | 0.330 |
Why?
|
| Adult | 28 | 2021 | 25182 | 0.310 |
Why?
|
| Interleukin-15 | 1 | 2007 | 71 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2012 | 239 | 0.300 |
Why?
|
| Interleukin-2 | 1 | 2007 | 242 | 0.290 |
Why?
|
| Quality of Life | 2 | 2012 | 1491 | 0.290 |
Why?
|
| Ganciclovir | 2 | 2002 | 49 | 0.280 |
Why?
|
| Syndrome | 3 | 2020 | 432 | 0.280 |
Why?
|
| Follow-Up Studies | 11 | 2016 | 3600 | 0.280 |
Why?
|
| Aged | 14 | 2022 | 18018 | 0.270 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2220 | 0.260 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 153 | 0.260 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 883 | 0.260 |
Why?
|
| Tissue Donors | 4 | 2017 | 437 | 0.260 |
Why?
|
| Risk Factors | 10 | 2017 | 5296 | 0.250 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 85 | 0.240 |
Why?
|
| Drug Monitoring | 3 | 2012 | 117 | 0.240 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1351 | 0.240 |
Why?
|
| Base Sequence | 2 | 2006 | 2312 | 0.240 |
Why?
|
| Incidence | 5 | 2014 | 1564 | 0.230 |
Why?
|
| Retrospective Studies | 12 | 2018 | 8037 | 0.230 |
Why?
|
| Uteroglobin | 2 | 2014 | 4 | 0.230 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 59 | 0.230 |
Why?
|
| Serum Amyloid P-Component | 2 | 2012 | 5 | 0.220 |
Why?
|
| Pulmonologists | 1 | 2022 | 4 | 0.220 |
Why?
|
| United States | 10 | 2022 | 6414 | 0.220 |
Why?
|
| Epithelial Cells | 2 | 2019 | 625 | 0.210 |
Why?
|
| Organophosphonates | 1 | 2001 | 50 | 0.210 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2001 | 245 | 0.210 |
Why?
|
| Cohort Studies | 9 | 2022 | 2695 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 2 | 2017 | 117 | 0.210 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 189 | 0.200 |
Why?
|
| Viral Load | 1 | 2001 | 141 | 0.200 |
Why?
|
| Nitric Oxide | 2 | 2000 | 275 | 0.200 |
Why?
|
| Survival Rate | 7 | 2018 | 1843 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 65 | 0.200 |
Why?
|
| Respiration, Artificial | 3 | 2000 | 328 | 0.200 |
Why?
|
| Frail Elderly | 1 | 2020 | 64 | 0.200 |
Why?
|
| Myositis | 1 | 2020 | 16 | 0.190 |
Why?
|
| Smoking | 3 | 2022 | 600 | 0.180 |
Why?
|
| Acute Disease | 5 | 2014 | 809 | 0.180 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2020 | 137 | 0.180 |
Why?
|
| Organ Transplantation | 2 | 2018 | 259 | 0.180 |
Why?
|
| Enterococcus | 1 | 1999 | 35 | 0.180 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 117 | 0.180 |
Why?
|
| Case-Control Studies | 7 | 2018 | 1775 | 0.170 |
Why?
|
| Bronchodilator Agents | 1 | 1999 | 61 | 0.170 |
Why?
|
| Vancomycin | 1 | 1999 | 70 | 0.170 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 185 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 6419 | 0.170 |
Why?
|
| Particulate Matter | 1 | 2018 | 63 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2019 | 257 | 0.160 |
Why?
|
| Immunoglobulin G | 3 | 2007 | 446 | 0.160 |
Why?
|
| Air Pollution | 1 | 2018 | 51 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 207 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1999 | 128 | 0.160 |
Why?
|
| Cells, Cultured | 3 | 2019 | 2762 | 0.160 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2017 | 18 | 0.160 |
Why?
|
| Metformin | 1 | 2018 | 115 | 0.160 |
Why?
|
| Transplantation Immunology | 3 | 2011 | 84 | 0.150 |
Why?
|
| Sirtuin 3 | 1 | 2017 | 30 | 0.150 |
Why?
|
| Respiratory Mucosa | 2 | 2022 | 86 | 0.150 |
Why?
|
| Stem Cells | 1 | 2019 | 342 | 0.150 |
Why?
|
| Cause of Death | 1 | 2018 | 273 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2000 | 300 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 181 | 0.150 |
Why?
|
| Aging | 1 | 2020 | 659 | 0.140 |
Why?
|
| Logistic Models | 6 | 2018 | 1155 | 0.140 |
Why?
|
| Hyperoxia | 1 | 2016 | 35 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2018 | 698 | 0.140 |
Why?
|
| Apoptosis | 2 | 2017 | 1667 | 0.140 |
Why?
|
| Thrombosis | 1 | 2018 | 283 | 0.140 |
Why?
|
| Prognosis | 5 | 2017 | 3616 | 0.140 |
Why?
|
| Ureaplasma | 1 | 2015 | 4 | 0.140 |
Why?
|
| Ureaplasma Infections | 1 | 2015 | 3 | 0.140 |
Why?
|
| Cell Separation | 1 | 2016 | 192 | 0.140 |
Why?
|
| Immunophenotyping | 1 | 2016 | 210 | 0.140 |
Why?
|
| Hyperammonemia | 1 | 2015 | 10 | 0.140 |
Why?
|
| Length of Stay | 3 | 2007 | 683 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2018 | 573 | 0.130 |
Why?
|
| Transcriptome | 1 | 2019 | 545 | 0.130 |
Why?
|
| Mitochondria | 1 | 2018 | 528 | 0.130 |
Why?
|
| Anaphylatoxins | 1 | 2014 | 1 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 2317 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 966 | 0.130 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2014 | 5 | 0.130 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 10 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2014 | 7773 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1635 | 0.130 |
Why?
|
| Solubility | 1 | 2014 | 174 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2016 | 668 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 701 | 0.120 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 8 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2410 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2007 | 1356 | 0.120 |
Why?
|
| Genetic Markers | 3 | 2021 | 474 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 375 | 0.120 |
Why?
|
| Adolescent | 5 | 2013 | 8803 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 124 | 0.120 |
Why?
|
| DNA, Viral | 3 | 2002 | 262 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 854 | 0.120 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 18 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 189 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 32 | 0.110 |
Why?
|
| Cytokines | 2 | 2018 | 754 | 0.110 |
Why?
|
| ROC Curve | 2 | 2014 | 743 | 0.110 |
Why?
|
| Pulmonary Medicine | 1 | 2012 | 45 | 0.110 |
Why?
|
| Lung Injury | 1 | 2012 | 45 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 285 | 0.110 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 564 | 0.110 |
Why?
|
| Hemodynamics | 3 | 2000 | 693 | 0.110 |
Why?
|
| Observer Variation | 1 | 2013 | 594 | 0.100 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 7 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 2 | 2002 | 72 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2007 | 918 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2496 | 0.100 |
Why?
|
| Cell Differentiation | 3 | 2017 | 1394 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2013 | 404 | 0.100 |
Why?
|
| Cyclosporine | 1 | 2011 | 234 | 0.100 |
Why?
|
| Prednisone | 1 | 2010 | 254 | 0.090 |
Why?
|
| Genetic Variation | 2 | 2015 | 1351 | 0.090 |
Why?
|
| Patient Readmission | 2 | 2010 | 312 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2018 | 2220 | 0.090 |
Why?
|
| Obesity | 2 | 2017 | 936 | 0.090 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2007 | 66 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 921 | 0.090 |
Why?
|
| Young Adult | 4 | 2018 | 5835 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 136 | 0.090 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 125 | 0.090 |
Why?
|
| Serum Response Factor | 1 | 2009 | 44 | 0.090 |
Why?
|
| Illinois | 2 | 2001 | 459 | 0.090 |
Why?
|
| Immunoassay | 1 | 2008 | 90 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 1746 | 0.080 |
Why?
|
| Consensus | 2 | 2021 | 308 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 122 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 304 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2018 | 3178 | 0.080 |
Why?
|
| Fibrosis | 2 | 2020 | 194 | 0.080 |
Why?
|
| Immunity | 1 | 2008 | 126 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2009 | 228 | 0.080 |
Why?
|
| Genotype | 4 | 2015 | 1828 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 310 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1558 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2647 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 275 | 0.080 |
Why?
|
| Animals | 8 | 2019 | 25939 | 0.080 |
Why?
|
| Critical Pathways | 1 | 2007 | 34 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 573 | 0.080 |
Why?
|
| Photopheresis | 2 | 2011 | 12 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1967 | 0.070 |
Why?
|
| Phenotype | 4 | 2016 | 2314 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 20 | 0.070 |
Why?
|
| Mice | 5 | 2018 | 10897 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2009 | 699 | 0.070 |
Why?
|
| Disease Progression | 1 | 2010 | 1469 | 0.070 |
Why?
|
| Genome, Viral | 1 | 2006 | 73 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 398 | 0.070 |
Why?
|
| Multigene Family | 1 | 2006 | 204 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2184 | 0.070 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 94 | 0.070 |
Why?
|
| Safety | 1 | 2005 | 152 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2006 | 300 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 682 | 0.060 |
Why?
|
| Intubation, Intratracheal | 2 | 2007 | 143 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 411 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 851 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2011 | 1530 | 0.060 |
Why?
|
| Lipids | 1 | 2005 | 266 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 917 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 49 | 0.060 |
Why?
|
| Waiting Lists | 2 | 2006 | 165 | 0.060 |
Why?
|
| RNA | 1 | 2006 | 531 | 0.060 |
Why?
|
| Administration, Inhalation | 2 | 2000 | 185 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 1889 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 351 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2001 | 69 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2001 | 38 | 0.050 |
Why?
|
| Contraindications | 1 | 2021 | 70 | 0.050 |
Why?
|
| Cell Line | 2 | 2018 | 2429 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 290 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 673 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2001 | 55 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 761 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 144 | 0.050 |
Why?
|
| Inflammation | 1 | 2006 | 874 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2002 | 494 | 0.050 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2000 | 37 | 0.050 |
Why?
|
| Marijuana Smoking | 1 | 2000 | 29 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2001 | 182 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 823 | 0.050 |
Why?
|
| Cytosine | 1 | 2001 | 125 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2006 | 676 | 0.050 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 31 | 0.050 |
Why?
|
| Cocaine-Related Disorders | 1 | 2000 | 34 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2000 | 111 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2000 | 143 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2012 | 668 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 421 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 357 | 0.050 |
Why?
|
| Global Health | 1 | 2021 | 194 | 0.050 |
Why?
|
| Collagen Type V | 1 | 2019 | 2 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 183 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2000 | 183 | 0.040 |
Why?
|
| Pneumonia | 1 | 2000 | 171 | 0.040 |
Why?
|
| Tubulin | 1 | 2019 | 58 | 0.040 |
Why?
|
| Heart-Lung Transplantation | 1 | 1999 | 17 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2019 | 62 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1066 | 0.040 |
Why?
|
| Electron Transport | 1 | 2018 | 71 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 132 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 253 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2000 | 147 | 0.040 |
Why?
|
| Autoantigens | 1 | 2019 | 122 | 0.040 |
Why?
|
| Hospitals, University | 1 | 1999 | 193 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 1999 | 76 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2018 | 79 | 0.040 |
Why?
|
| Reoperation | 1 | 2000 | 587 | 0.040 |
Why?
|
| Rectum | 1 | 1999 | 153 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2019 | 154 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 1999 | 65 | 0.040 |
Why?
|
| Critical Care | 1 | 2000 | 358 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2018 | 239 | 0.040 |
Why?
|
| Asbestos | 1 | 2017 | 22 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 39 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 97 | 0.040 |
Why?
|
| Oxidants | 1 | 2017 | 85 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 684 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 109 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2016 | 44 | 0.040 |
Why?
|
| Monocytes | 1 | 2017 | 212 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2015 | 35 | 0.040 |
Why?
|
| Age Factors | 1 | 2000 | 1817 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 460 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 1999 | 358 | 0.040 |
Why?
|
| Ammonia | 1 | 2015 | 37 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 356 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 69 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 66 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1948 | 0.030 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2014 | 2 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 133 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2015 | 189 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2014 | 67 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 679 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 66 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 68 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 74 | 0.030 |
Why?
|
| Granzymes | 1 | 2013 | 91 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2013 | 48 | 0.030 |
Why?
|
| Proteolysis | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1883 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 227 | 0.030 |
Why?
|
| Resistin | 1 | 2011 | 8 | 0.030 |
Why?
|
| Adiponectin | 1 | 2011 | 24 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 3024 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2011 | 13 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 733 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 393 | 0.030 |
Why?
|
| Leptin | 1 | 2011 | 99 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 49 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 68 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 82 | 0.030 |
Why?
|
| Overweight | 1 | 2011 | 115 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 525 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 177 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 112 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 638 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 987 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 372 | 0.020 |
Why?
|
| Heart Failure | 1 | 1999 | 1147 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1197 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 95 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 233 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2009 | 260 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 399 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 540 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 440 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2006 | 117 | 0.020 |
Why?
|
| Glycosylation | 1 | 2006 | 128 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2006 | 75 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1033 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2006 | 174 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2006 | 311 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2007 | 277 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 863 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2002 | 116 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 2057 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 805 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3024 | 0.010 |
Why?
|
| Shock | 1 | 2000 | 41 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 345 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2000 | 949 | 0.010 |
Why?
|
| Hypoxia | 1 | 2000 | 619 | 0.010 |
Why?
|
| Child | 1 | 2006 | 6697 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 3882 | 0.010 |
Why?
|